Clinical Implications of the p53 Tumor-Suppressor Gene
- 28 October 1993
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 329 (18) , 1318-1327
- https://doi.org/10.1056/nejm199310283291807
Abstract
The crucial differences between normal cells and cancer cells stem from discrete changes in specific genes controlling proliferation and tissue homeostasis. Over 100 such cancer-related genes have been discovered, several of which are implicated in the natural history of human cancer because they are consistently found to be mutated in tumors. The p53 tumor-suppressor gene is the most striking example because it is mutated in about half of almost all types of cancer arising from a wide spectrum of tissues. Other tumor-suppressor genes important in human cancers, such as adenomatous polyposis coli, Wilms' tumor type 1, and neurofibromatosis type 1, . . .Keywords
This publication has 101 references indexed in Scilit:
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993
- p53 codon 249ser hot-spot mutation in HBV-negative hepatocellular carcinomaThe Lancet, 1993
- Alterations in the structural gene and the expression of p53 in rat liver tumors induced by aflatoxin B1Molecular Carcinogenesis, 1992
- Kinds of mutations induced by aflatoxin B1 in a shuttle vector replicating in human cells transiently expressing cytochrome P450IA2 cDNAMolecular Carcinogenesis, 1992
- The p53 tumour suppressor geneNature, 1991
- Familial cancer syndromes and clustersCurrent Problems in Cancer, 1990
- Mutational Spectrometry in Animal Toxicity TestingAnnual Review of Pharmacology and Toxicology, 1990
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989
- MUTATIONAL SPECIFICITY IN BACTERIAAnnual Review of Genetics, 1983